CDKN2A and breast carcinoma: It is believed that intact RB is required in order for a CDK4/6 inhibitor to be effective in ER+ breast cancer, but cyclin D1 overexpression or loss of p16INK4A did not predict response to palbociclib in the PALOMA-1 study36.